TILATAMIG SAMROTECAN
UNII BL5C53FB6H
Substance Identification & Data
This profile provides standardized clinical and technical data for Tilatamig Samrotecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) BL5C53FB6H.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2868265-77-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
BL5C53FB6H
2868265-77-2
N/A
Detailed Substance Profile
Preferred Name
TILATAMIG SAMROTECAN
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13021
Sequential identifier assigned via the WHO International Nonproprietary Name program.
USAN ID
NO-14
Identifier assigned by the United States Adopted Names Council.
Substance Type
Tilatamig Samrotecan
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Tilatamig Samrotecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
Common Names & Synonyms
H-gamma1 heavy chain anti-MET Homo sapiens (1-446) [VH (Homo sapiens IGHV1-8*01 (95.9%) -(IGHD) -IGHJ3*01 (100%), CDR-IMGT [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, CH3 E12, M14, G1v39 CH2 F1.3, E1.2, S116, G1v33 CH3 S22, A24, V86 (hole), G1v75 CH3 C5 (CH1 R120 (213) (117-214), hinge 1-15 (215-229), CH2 L1.3>F (233), L1.2>E (234), P116>S (330) (230-339), CH3 Y5>C (348), E12 (355), M14 (357) T22>S (365), L24>A (367), Y86>V (406) (hole) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with L-kappa light chain anti-MET Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-5*03 (92.6%) -IGKJ4*01 (90.9%) V124>L (104'), CDRIMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; H-gamma1 heavy chain anti-EGFR Homo sapiens (1''-454'') [VH (Homo sapiens IGHV1-69*06 (83.7%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [8.8.17] (26''-33''.51''-58''.97''-113'')) (1''-124'') -Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, CH3 E12, M14, G1v39 CH2 F1.3, E1.2, S116, G1v32 CH3 W22 (knob), G1v74 CH3 C10, G1v58 CH1 C5, h V5 (CH1 F5>C (133''), R120 (221'') (125''-222''), hinge 1-15 C5>V (227'') (223''-237''), CH2 L1.3>F (241''), L1.2>E (242''), P116>S (338'') (238''-347''), CH3 S10>C (361''), E12 (363''), M14 (365''), T22>W (373'') (348''-452''), CHS (453''-454'')) (125''-454'')], (133''-126''')-disulfide with L-lambda2 light chain anti-EGFR Homo sapiens (1'''-217''') [V-LAMBDA (Homo sapiens IGLV2-14*05 (94.9%) -IGLJ2*01 (90.9%), CDR-IMGT [9.3.11] (26'''-34'''.52'''-54'''.91'''-101''')) (1'''-111''') -Homo sapiens IGLC2*01 (98.1%), LC2v58 C10, V126, S10>C (126'''), C126>V (216''') (112'''-217''')]; dimer (225-233'':228-236'')-bisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa; substituted at the sulfur atoms of L-cysteinyl residues 233, 236, 219'', 225'', 228'' and 214''' with radical group 1-[(2S,5S)-1-{[(9S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12Hbenzo[ de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]amino}-2-methyl-1,4,7,35-tetraoxo-5-(propan-2-yl)-10,13,16,19,22,25,28,31-octaoxa-3,6,34-triazaheptatriacontan-37-yl]-2,5-dioxopyrrolidin-3-yl (samrotecan)
Immunoglobulin G1 [133-cysteine,227-valine,241-phenylalanine,242-glutamic acid,338-serine, 361-cysteine,373-tryptophan], anti-(human epidermal growth factor receptor) (human monoclonal RAA22 γ1-chain), (133→126′′)-disulfide with [126-cysteine,216-valine] human monoclonal RAA22 λ-chain, (361→348′)-disulfide with immunoglobulin G1 [233-phenylalanine,234-glutamic acid,330-serine,348-cysteine,365-serine,367-alanine,406-valine] anti-(human hepatocyte growth factor receptor C-Met) (human monoclonal B09 γ1-chain) complex with human monoclonal B09 κ-chain, 214′′,219,225,228,233′,236′-hexakis(thioether) with N-[31-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1,29-dioxo-4,7,10,13,16,19,22,25-octaoxa-28-azahentriacont-1-yl]-L-valyl-N-[(9S)-9-ethyl-2,3,9,10,13,15-hexahydro-9-hydroxy-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl]-L-alaninamide
TILATAMIG SAMTOTECAN [USAN]
Tilatamig Samrotecan
immunoglobulin G1-kappa/G1-lambda, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens monoclonal antibody, bispecific, conjugated on 6 cysteinyl residues to samrotecan
tilatamig samrotecan [INN]
